AC Immune SA reported total cash resources of CHF 73.9 million as of September 30, 2026, providing a capital runway into the first quarter of 2028. The company posted a net loss of CHF 8.8 million for the third quarter, compared to CHF 15.9 million in the prior year period, while revenue increased to CHF 3.2 million from CHF 0.9 million due to Takeda arrangement recognitions. Clinically, ACI-7104 received FDA Fast Track designation and IND clearance, with positive safety and immunogenicity results reported through week-100 of the Phase 2 VacSYn trial in Parkinson’s disease. Additionally, a lead candidate was selected for the Morphomer small molecule program targeting alpha-synuclein, and ACI-19764 showed positive interim safety results in a Phase 1 trial. Tom Graney joined the board while Dr. Carl June stepped down. The company is a clinical-stage biopharma developing therapies for neurodegenerative diseases.
